FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549	
vasimigton,	D.O.	20040	

STATEMENT	OF C	HANGES	IN BENEFI	ICIAL (	OWNERSH	ΙP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response	: 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Brege Laura				2. Issuer Name and Ticker or Trading Symbol Pacira BioSciences, Inc. [ PCRX ]  5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify								wner							
(Last) (First) (Middle) C/O PACIRA BIOSCIENCES, INC.							3. Date of Earliest Transaction (Month/Day/Year) 06/09/2021								below)			Other (: below)	sреспу 
5 SYLVAN WAY, SUITE 300							4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable				
(Street) PARSIPI	PANY N	J	07054												X Form filed by One Reporting Person Form filed by More than One Reporting Person			I	
(City)	(S	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution Date,		Code (Instr.   5)						s Form ally (D) o ollowing (I) (Ir		n: Direct r Indirect sstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) or (D)		;	Transact	saction(s) r. 3 and 4)			(111301.4)	
Common Stock 06/09/					9/2021	′2021		A		1,066	066 <sup>(1)</sup> A \$		.00	8,987			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,		ransaction Code (Instr. )		of E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab	le E	expiration Date	Title	Amour or Number of Shares	r					
Stock Option (Right to Buy)	\$60.96	06/09/2021			A		7,626		06/09/202	2 0	6/09/2031	Common Stock	7,626	5	\$0.00	7,626		D	

## **Explanation of Responses:**

1. Represents restricted stock units that vest on June 3, 2022, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

## Remarks:

/s/ Kristen Williams, Attorney-06/11/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.